Intismeran autogene

N/A

Report date: 2026/05/16 20:00:17

Base Information

Drug NameIntismeran autogene
Drug Alias NamePersonalized Cancer VaccinemRNA-4157mRNA-4157/V940V-940PCV
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccine > personalized mRNA cancer vaccines
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[44] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesModerna Inc
China Registration ClassN/A

Develop Information

Active CompaniesModerna IncMerck Sharp & Dohme LLC
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsSkin NeoplasmsCarcinoma, Squamous Cell

Other Information

ATC CodeN/A
Related LinksN/A